Long-term outcomes after deep venous thrombosis of the lower extremities

Vascular Medicine

Volumn 3, Issue 1, 1998, Pages 57-60

  Prandoni, Paolo ^a   Lensing, Anthonie W A ^b   Prins, Martin R ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Factor V Leiden; Post thrombotic syndrome; Thrombophilia; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; HUMAN; LEG COMPRESSION; LEG THROMBOSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL;

EID: 0031804869     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9800300112     Document Type: Review

References (31)

1. Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism N Engl J Med 1995; 332: 1661-65.
2. Franzeck UK, Schalch I, Jager KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich Study). Circulation 1996; 93: 74-79.
3. Brandjes DPM, Büller HR, Heijboer H et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62
4. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
5. 506→ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
6. Ridker PM, Miletich P, Stampfer MJ et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 91: 2800-802.
7. Ridker PM, Hennekens CH, Lindpaintner K et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-17
8. Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis N Engl J Med 1995; 332: 1710-11.
9. Chesterman CN. After a first episode of venous thromboembolism. BMJ 1995; 311: 700-701.
10. Immelman EJ, Jeffrey PC. The postphlebitic syndrome. Pathophysiology, prevention and management. Clin Chest Med 1984; 5: 537-50.
11. Villalta S, Bagatella P, Picioli A, Lensing AWA, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for post-thrombotic syndrome. Haemostasia 1994; 24(suppl 1): 158A.
12. Bauer GA. Roentgenological and clinical study of the sequels of thrombosis. Acta Chir Scand 1942; 86(suppl 74): 1-110.
13. Gjores J. The incidence of venous thrombosis and its sequelae in certain districts of Sweden Acra Chir Scand 1956; 206(suppl 1): 1-88.
14. O'Donnell FF, Browse NL, Burnand KG, Lea Thomas M. The socioeconomic effects of an ilio-femoral venous thrombosis. J Surg Res 1977; 22: 483-88.
15. Strandness DE, Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis JAMA 1983; 250: 1289-92
16. Widmer LK, Kemp E, Widmer MTH et al. Late results in deep-vein thrombosis of the lower extremities. VASA 1985; 14: 264-68.
17. Lindner DJ, Edwards JM, Phinney ES, Taylor LM, Porter JM. Long-term hemodynamic and clinical sequelae of lower extremity deep-vein thrombosis. J Vasc Surg 1986; 4: 436-42.
18. Heldal M, Seem E, Snadset PM, Abildgaard U. Deep-vein thrombosis: a 7-year follow-up study. J Intern Med 1993; 234: 71-75.
19. Monreal M, Martorell A, Callejas JM et al. Venographic assessment of deep-vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. J Intern Med 1993; 233: 854-59.
20. Milne AA, Ruckley CV The clinical course of patients following extensive deep venous thrombosis. Eur J Vasc Surg 1994; 8: 56-59
21. Saarinen J, Sisto T, Laurikka J, Salenius JP, Tarkka M Late sequelae of acute deep venous thrombosis: evaluation five and ten years after. Phlebology 1995; 10: 106-109.
22. Beyth RJ, Cohen AM, Landefeld S. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155: 1031-37.
23. Brandjes DPM, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis N Engl J Med 1992; 327: 1485-89.
24. Hull RD, Raskob GE, Hirsh J et al Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
25. Hull RD, Raskob GE, Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-64.
26. Prandoni P, Lensing AWA, Büller HR et al. Comparison of subcutaneous low molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-45
27. Hull RD, Raskob GL, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
28. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-87.
29. Levine M, Gent M, Hirsh J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
30. Prandoni P, Lensing AWA, Büller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33
31. Carson JL, Kelley MA, Duff A et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326: 1240-45.